Trial Profile
Phase II trial of second line therapy with Oxaliplatin and Pemetrexed in patients with advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 26 May 2011 New trial record